Martek Announces Addition to Its Board of Directors

COLUMBIA, Md., Sept. 16 /PRNewswire-FirstCall/ -- Martek Biosciences (Nasdaq: MATK) today announced the election of David M. Pernock to its Board of Directors.

Mr. Pernock brings to Martek's Board an extensive background in the commercialization of pharmaceutical products, having served from 1994 to 2009 in a variety of executive capacities for GlaxoSmithKline (GSK), one of the world's leading healthcare companies. In his most recent executive role, Mr. Pernock served as Senior Vice President in charge of GSK's pharmaceutical, vaccines, oncology, acute care and HIV divisions in the United States.

Mr. Pernock holds a Bachelor of Science degree in Business Administration from Arizona State University. He also currently serves on the Board of Directors of InstantDX, LLC, a privately-held provider of electronic prescribing services.

"We are pleased that David Pernock has accepted a position on Martek's Board," said Robert J. Flanagan, Martek's Chairman of the Board. "David's extensive experience in the healthcare industry provides Martek with a valuable resource."

Martek Biosciences Corporation is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com.

    CONTACT
    Cassie France-Kelly
    Public Relations
    (443) 542-2116
    cfrancekelly@martek.com

    Kyle Stults
    Investor Relations
    (410) 740-0081
    investors@martek.com

SOURCE Martek Biosciences Corporation